New York, United States
According to Aisling Capital, an era of healthcare revolution is imminent as the biotechnology industry generates new therapeutics. With the human genome project now completed, scientific understanding of human disease causation has improved. This newfound knowledge, combined with the biotech sector's advancements of the past two decades, is facilitating swift progress in innovative strategies for preventing, diagnosing, and treating fatal ailments.
77
Total Investments
53
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Biotechnology, Health Care
Funding Stage
Series A +1
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Aisling Capital
Recent Investments (77)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series C | •••••• | Aug 2025 | |
| Post-IPO Equity | •••••• | Jan 2024 | |
| Series C | •••••• | Dec 2023 | |
| Post Ipo Debt | •••••• | Aug 2023 | |
| Series B | •••••• | Feb 2023 | |
•••• ••••
|
Series C | •••••• | Sep 2022 |
|
•••• ••••
|
Series B | •••••• | Jun 2022 |
|
•••• ••••
|
Series B | •••••• | Jul 2021 |
|
•••• ••••
|
Series B | •••••• | Apr 2021 |
|
•••• ••••
|
Series C | •••••• | Mar 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
